Drug Profile

SRN 101 - Siren Biotechnology

Alternative Names: SRN-101 - Siren Biotechnology

Latest Information Update: 27 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Siren Biotechnology
Class Antineoplastics; Cytokine genes; Gene therapies; Immunotherapies
Mechanism of Action Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Glioma
New Molecular Entity No

Highest Development Phases

Preclinical Glioma; Solid tumours

Most Recent Events

24 Feb 2026 SRN 101 - Siren Biotechnology receives Fast Track designation for Glioma [Parenteral] in USA
28 Jan 2026 US FDA approves IND application for SRN 101 in Glioma
28 Jan 2026 Siren Biotechnology plans a first in human trial for Glioma (Recurrent)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com